Prevention of strongyloides hyperinfection syndrome: a rheumatological point of view
- PMID: 19892301
- DOI: 10.1016/j.ejim.2009.09.001
Prevention of strongyloides hyperinfection syndrome: a rheumatological point of view
Abstract
Background: Strongyloides stercoralis (S.stercoralis) is a parasite that infects humans and in conditions of immunodeficiency may disseminate, causing the potentially fatal strongyloides hyperinfection syndrome (SHS). The aim of this review was to investigate the literature evidence on the prophylaxis of SHS in immunosuppressed patients with rheumatological disorders.
Material and methods: The MEDLINE database (from 1966 to 2008) was searched using the following terms: "strongyloidiasis", "disseminated strongyloidiasis", "Strongyloides stercoralis", "Strongyloides stercoralis dissemination", "strongyloides hyperinfection syndrome", "treatment", "prophylaxis", "prevention", "immunocompromised", "immunodepression", "immunosuppressed", "immunosuppression", "corticosteroids", "glucocorticoids", "lupus erythematosus", "rheumatoid arthritis", "rheumatic diseases". A search of the therapeutic studies using the same set of terms was carried out.
Results: No study on the prophylaxis of SHS restricted to rheumatic immunosuppressed patients was identified. However, two articles have been published on the prophylaxis of strongyloidiasis in other immunosuppressed patients. Additionally, 13 studies dealing with different therapeutical options for strongyloidiasis were identified and presented.
Conclusions: Since there is no evidence on the prophylaxis of SHS in immunosuppressed rheumatic patients, the suggested regimen for that prophylaxis may rely on the results obtained from therapeutical studies. Ivermectin has the best safety profile, lower cost and best efficacy and should be the drug of choice for the prophylaxis of SHS in such patients. Although a definitive prophylactic regimen has not been defined, the option for 200 microg/kg/day for 2 days, repeated within 2 weeks, seems to be a reasonable approach. Such regimen should be repeated every 6 months in case of persisting immunosuppression in permanent residents of endemic areas.
Comment in
-
Srongyloides hyperinfection syndrome: how to prevent?Eur J Intern Med. 2010 Jun;21(3):e21; author reply e22. doi: 10.1016/j.ejim.2010.01.008. Epub 2010 Feb 1. Eur J Intern Med. 2010. PMID: 20493408 No abstract available.
Similar articles
-
Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection.Ann Pharmacother. 2007 Dec;41(12):1992-2001. doi: 10.1345/aph.1K302. Epub 2007 Oct 16. Ann Pharmacother. 2007. PMID: 17940124 Review.
-
Strongyloides hyperinfection in rheumatoid arthritis.Int J Surg Pathol. 2007 Oct;15(4):391-2. doi: 10.1177/1066896907302241. Int J Surg Pathol. 2007. PMID: 17913948 No abstract available.
-
Strongyloides stercoralis hyperinfection in systemic lupus erythematosus and the antiphospholipid syndrome.Semin Arthritis Rheum. 2006 Dec;36(3):135-43. doi: 10.1016/j.semarthrit.2006.06.001. Epub 2006 Sep 1. Semin Arthritis Rheum. 2006. PMID: 16949135 Review.
-
Strongyloides hyperinfection syndrome after intestinal transplantation.Transpl Infect Dis. 2008 Apr;10(2):137-41. doi: 10.1111/j.1399-3062.2007.00256.x. Epub 2007 Jul 1. Transpl Infect Dis. 2008. PMID: 17605735
-
Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation.Transpl Infect Dis. 2009 Apr;11(2):143-8. doi: 10.1111/j.1399-3062.2008.00360.x. Epub 2008 Dec 17. Transpl Infect Dis. 2009. PMID: 19144095
Cited by
-
Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases.RMD Open. 2022 Nov;8(2):e002726. doi: 10.1136/rmdopen-2022-002726. RMD Open. 2022. PMID: 36323488 Free PMC article. Review.
-
Disseminated Strongyloides stercoralis infection in HTLV-1-associated adult T-cell leukemia/lymphoma.Acta Haematol. 2011;126(2):63-7. doi: 10.1159/000324799. Epub 2011 Apr 7. Acta Haematol. 2011. PMID: 21474923 Free PMC article.
-
Severe strongyloidiasis and systemic vasculitis: comorbidity, association or both? Case-based review.Rheumatol Int. 2018 Dec;38(12):2315-2321. doi: 10.1007/s00296-018-4178-y. Epub 2018 Oct 23. Rheumatol Int. 2018. PMID: 30353268 Review.
-
Should we look for Strongyloides stercoralis in foreign-born HIV-infected persons?J Immigr Minor Health. 2013 Aug;15(4):796-802. doi: 10.1007/s10903-012-9756-6. J Immigr Minor Health. 2013. PMID: 23233123
-
Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study.Mult Scler. 2011 Jun;17(6):743-54. doi: 10.1177/1352458511398054. Epub 2011 Mar 3. Mult Scler. 2011. PMID: 21372112 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
